PeptideLabs Logo
PeptideLabs
All profiles

Ipamorelin

Is researched for its effect on growth-hormone pulses; benefit and safety are unconfirmed.

Not FDA-approved
LibraryNo account · this device only

Use at a glance

Ipamorelin

Is researched for its effect on growth-hormone pulses; benefit and safety are unconfirmed.

The reference presents a stepped model. This table records it for context; it is not a starting or escalation plan.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

Daily amount
100 µg/day
Period
Week 1
Community phase
Assessment
Described timing
once at bedtime, fasted
View preparationCheck sources
Overview of all entries

  • Ipamorelin · Assessment

    Period:
    Week 1
    Daily amount:
    100 µg/day
    Described timing:
    once at bedtime, fasted

  • Ipamorelin · Titration

    Period:
    Weeks 2–3
    Daily amount:
    200 µg/day
    Described timing:
    once at bedtime or 100 µg AM + 100 µg PM

  • Ipamorelin · Common model

    Period:
    Weeks 4–8
    Daily amount:
    200–300 µg/day
    Described timing:
    once or twice daily; fasted AM and/or bedtime

  • Ipamorelin · Extended

    Period:
    Weeks 9–12
    Daily amount:
    200–300 µg/day
    Described timing:
    community continuation if tolerated; sometimes to week 16

  • Ipamorelin · Break

    Period:
    4 weeks
    Daily amount:
    0 µg
    Described timing:
    described as an off-cycle
More factsAt a glance

Plain-language overview

Is researched for its effect on growth-hormone pulses; benefit and safety are unconfirmed.

How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
When and for how long?
No generally established use schedule. Study schedules and community claims are distinguished below.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
All amounts and schedules
Sources
Class
Ghrelin-receptor agonist / GH secretagogue
Human PK
about 2-hour terminal half-life
Approval
No FDA approval
Anti-doping
WADA: prohibited at all times

Human studies show short pharmacokinetics and GH release after intravenous administration. They do not establish an approved subcutaneous dose or benefits for anti-ageing, muscle gain, fat loss, sleep or recovery. The schedules below come from the reference page and commonly circulated community models. They have not been confirmed in controlled trials for these goals.

Cycle modelsNot established: no approved schedule supports these subcutaneous amounts, escalation steps, frequencies or breaks. A claimed ceiling around 300 µg and totals up to 900 µg/day are also community claims, not established safety limits.

Not established: no approved schedule supports these subcutaneous amounts, escalation steps, frequencies or breaks. A claimed ceiling around 300 µg and totals up to 900 µg/day are also community claims, not established safety limits.

Described timing

  • Community sources commonly place administrations at bedtime or fasted in the morning.
  • They often mention 1–2 hours after food and 20–30 minutes before eating; a benefit for these community schedules is not clinically validated.
  • One to three times per day are discussed. Missed administrations are generally not doubled in these models.
  • Published research has not established separate subcutaneous standard doses for women and men for these goals.

Cycle models

Eight to twelve weeks followed by a four-week break is commonly cited; some models continue to 16 weeks. Neither the benefit and safety of these durations nor claimed receptor recovery during a break has been clinically established.

Daily-total arithmetic only

These examples only multiply amount per administration by frequency. They do not define an appropriate amount.

Amount each time

100 µg

Frequency
once daily
Calculated daily total
100 µg/day

Amount each time

100 µg

Frequency
twice daily
Calculated daily total
200 µg/day

Amount each time

200 µg

Frequency
once daily
Calculated daily total
200 µg/day

Amount each time

300 µg

Frequency
three times daily
Calculated daily total
900 µg/day

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

Simple syringe and pen calculator

Choose your device and enter your known values. One result appears below.

You know the total solution volume. Calculate the scale mark for your entered amount.

Which syringe or pen?
More syringes
How much substance is in the vial?

Total amount on the label—not the container size in ml.

What is the total solution volume?

This is the total solution after dissolving, not automatically the water to add. Follow the specific product's instructions for preparation.

Which known amount do you want to convert?

Your known input. The calculator does not choose a suitable amount.

Complete the three number fields to see a result.

The calculator chooses neither a dose nor a mixing liquid. It does not check sterility, stability or suitability for use.

What the units mean
  • mg / µg = substance amount. 1 mg = 1,000 µg.
  • ml = liquid volume, not substance amount.
  • U / clicks = device markings. Their meaning depends on the device scale.
Calculation and extra figures

Complete the three number fields to see a result.

Scale and precision notes

Arithmetic does not establish measurement accuracy. Displayed numbers may be rounded; very small numbers use scientific notation. Intermediate values may not be readable on your device. Do not round fractional clicks up or down.

U-100 is used as a volume scale: 100 U = 1 ml. It is not the substance amount.

Copy this value from your pen's instructions. A 3 ml cartridge does not tell you the volume delivered at 60 clicks.

Source for the U-100 scale
See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Vial size is not an administration amount

2 mg, 5 mg or 10 mg describes the claimed total amount in the vial. Added fluid changes concentration and volume, not the total micrograms.

Vial

2 mg

Assumed final volume
1.0 ml
Concentration
2,000 µg/ml
100 µg
0.05 ml / 5 U
200 µg
0.10 ml / 10 U
300 µg
0.15 ml / 15 U

Vial

5 mg

Assumed final volume
2.0 ml
Concentration
2,500 µg/ml
100 µg
0.04 ml / 4 U
200 µg
0.08 ml / 8 U
300 µg
0.12 ml / 12 U

Vial

10 mg

Assumed final volume
3.0 ml
Concentration
3,333 µg/ml
100 µg
0.03 ml / 3 U
200 µg
0.06 ml / 6 U
300 µg
0.09 ml / 9 U

Rounded values from the reference. Label, actual volume and syringe scale must be independently verified.

Formulas and individual stepsOpen only if you want the deeper explanation.

The values show only the concentration that would result if the stated vial amount were accurate and the exact fluid volume were added. U-100 means 100 units per 1 ml; one unit is 0.01 ml.

Formulas used

  • Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
  • Volume (ml) = target µg ÷ concentration
  • U-100 units = volume ml × 100

Mixing process described by the reference

  1. 01

    Verify inputs

    Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.

  2. 02

    Disinfect stoppers

    The reference calls for separate alcohol swabs and sterile single-use materials.

  3. 03

    Add fluid slowly

    The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.

  4. 04

    Dissolve gently

    The vial is rolled or swirled gently, not shaken, until no visible solids remain.

  5. 05

    Inspect visually

    Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.

  6. 06

    Label and store by product data

    Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.

An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.

Supply arithmetic from the reference

The source models 200 µg daily from a 10-mg vial with 3 ml fluid: about 50 calculated portions per vial, one vial for four weeks and two for 8–12 weeks. This is not medical planning or a recommendation; affiliate offers were excluded.

  • At 200 µg per calculated portion, 2/5/10 mg yields a theoretical 10/25/50 portions per vial.
  • For 4/8/12 weeks, that is arithmetically 3/6/9 vials of 2 mg, 2/3/4 vials of 5 mg, or 1/2/2 vials of 10 mg.
  • 28/56/84 administrations equal 28/56/84 disposable syringes; a 10-ml fluid vial mathematically covers three 3-ml preparations. Losses change the total.
Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Published evidence

Mechanism: what is supported and what does not follow

Ipamorelin is a synthetic pentapeptide and agonist at the ghrelin/growth-hormone secretagogue receptor GHS-R1a. It triggered GH release in preclinical models.

A small phase-I study in healthy men found dose-proportional PK after intravenous infusion, an approximately two-hour terminal half-life and a single GH episode peaking near 0.67 hours.

Claims of selectivity over ACTH/cortisol derive mainly from rat and swine data. They do not establish safety for subcutaneous self-use or long-term exposure.

Target

GHS-R1a / ghrelin receptor

Immediate effect

Pulsatile GH release in studied models

Downstream marker

IGF-1 may change with repeated GH activity

Not established

Anti-ageing, muscle, fat-loss, sleep or recovery benefit

Not FDA-approved

Adverse effects and safety risks

Community reports and clinical evidence must remain separate. 'Mild' or 'selective' does not mean safe; FDA highlights major data gaps and potential risks for compounded injectable products.

Commonly reported by communities

  • headache, fatigue or tingling
  • water retention, bloating or joint stiffness
  • mild appetite increase
  • redness, stinging or a lump at an injection site

FDA-highlighted or plausible risks

  • immunogenicity from aggregation or peptide-related impurities
  • insufficient safety data for certain injectable routes
  • hyperglycaemia and possible impaired glucose tolerance
  • in an IV POI study: hypokalaemia, nausea, vomiting, abdominal distension and deaths; causality of the deaths was unclear

Do not self-use / obtain clinical review

There is no validated prescribing standard for these community goals. Particularly high-risk or poorly studied situations include:

  • pregnancy, breastfeeding, children and adolescents
  • active or recent cancer or an unexplained mass
  • diabetes, prediabetes or unstable glucose
  • severe heart/kidney disease, oedema or fluid retention
  • sleep apnoea or neurological/visual warning signs
  • medicines affecting glucose, hormones or fluid balance
  • tested sport under anti-doping rules

Warning signs to monitor

  • persistent headache or visual change
  • rapid swelling, breathlessness or chest pain
  • marked glucose increases
  • new numbness, wrist pain or worsening sleep-apnoea symptoms
  • fever or increasing redness, heat, pain or discharge at an injection site

Acute symptoms

Seek emergency medical care for breathing difficulty, chest pain, altered consciousness, severe allergic reaction, major visual symptoms or signs of serious infection.

Published evidence

Monitoring and laboratory markers

No established Ipamorelin monitoring standard exists for community use. These items are inferred from GH-axis risk and require professional interpretation, not self-diagnosis.

Marker / observation

IGF-1

Why it matters
Downstream GH-axis marker
Context
Interpret with age and baseline

Marker / observation

Fasting glucose & HbA1c

Why it matters
Potential insulin-sensitivity changes
Context
Professional baseline and trend review

Marker / observation

Lipid panel

Why it matters
Metabolic context
Context
Not validated as Ipamorelin-specific monitoring

Marker / observation

TSH & free T4

Why it matters
Separate thyroid-related symptoms
Context
Interpret clinically

Marker / observation

Blood pressure, weight, oedema

Why it matters
Fluid retention and cardiovascular context
Context
Symptoms matter more than one value

Marker / observation

Sleep-apnoea symptoms

Why it matters
GH-axis stimulation may be problematic
Context
Worsening requires review

The reference suggests review after about 6–8 weeks and every 3–6 months for longer use. These intervals are not an accepted standard and must never delay urgent care.

Published evidence

Clinical evidence

Evidence is narrow, addresses different questions and mainly uses intravenous administration. It does not validate the community protocols.

Source

Raun et al., 1998

Design
Preclinical; rats and swine
Result
GH secretagogue with relative selectivity in animals
Limit
No human safety or community-dose study

Source

Gobburu et al., 1999

Design
Phase I; 40 healthy men; IV infusion
Result
Dose-proportional PK; t½ ~2 h; GH peak ~40 min
Limit
No subcutaneous long-term or benefit protocol

Source

Beck et al., 2014 / NCT00672074

Design
Phase II; 117 bowel-surgery patients; IV
Result
No significant efficacy benefit in postoperative ileus
Limit
Different population, indication and route

Source

FDA PCAC review, 2024

Design
Regulatory evidence review
Result
Insufficient SC efficacy/safety data; recommendation against 503A inclusion
Limit
Regulatory assessment, not individual risk advice

Conclusion: pharmacological activity is demonstrated. Clinical efficacy and safety are not established for body composition, anti-ageing, sleep, recovery or the described subcutaneous schedules.

Community-reported

Storage and stability

Without validated product-specific stability data there is no universal shelf life. The reference lists these community ranges; manufacturer/pharmacy labelling takes priority.

State

Lyophilised powder

Stated range
−20 °C
Claim / limitation
source: long term; no universal product confirmation

State

Lyophilised powder

Stated range
2–8 °C
Claim / limitation
source: months; product and packaging dependent

State

Lyophilised powder

Stated range
room temperature
Claim / limitation
source: short shipping window/weeks; not a shelf-life guarantee

State

Reconstituted solution

Stated range
2–8 °C
Claim / limitation
source: up to about 28 days; unverified without product data

State

Frozen single-use aliquots

Stated range
−20 °C
Claim / limitation
source: 3–4 months; stability/container compatibility unconfirmed

Protect from light and avoid temperature cycling and repeated freeze-thaw. Discard cloudy, discoloured or particle-containing solutions; a clear solution can still be contaminated or incorrectly constituted.

Troubleshooting and common errors

01

Wrong fluid volume

More fluid changes concentration and ml/U-100 values. Recalculate from the actual volume; do not guess.

02

Cloudy, coloured or particulate

Do not use. Visible change may indicate instability or contamination.

03

Unknown vial amount

Correct conversion is impossible without a reliable total. A label or COA does not automatically prove sterility.

04

Missed time

Community models describe resuming rather than doubling. This is not clinical dosing advice.

05

Broken cold chain

Remaining shelf life cannot be safely inferred without product stability data. Obtain professional assessment or discard.

06

Persistent symptoms

Do not solve by further calculation or self-adjustment; pause and seek medical review.

Sources checked: 1 September 2026

Regulatory status and WADA

FDA approval

Ipamorelin is not FDA-approved for any human use. Clinical testing is not approval.

503A

The earlier 503A nomination was withdrawn in 2024. FDA still reviewed Ipamorelin and the committee recommended against adding it to the 503A bulks list. Removal from an interim category is not authorisation or approval.

503B

Ipamorelin acetate currently remains in FDA Category 2 for 503B compounding, citing potentially significant safety risks including immunogenicity and missing data for certain injectable routes.

WADA 2026

Ipamorelin is expressly listed under S2.2.4 as a GH secretagogue/ghrelin mimetic and is prohibited at all times, in and out of competition.

Other jurisdictions

US compounding categories do not transfer to Switzerland or the EU. Possession, import, supply, use and professional responsibility require current local assessment.

Published evidence

Comparison with related substances

This compares targets, evidence and regulatory context; it is not a selection guide.

Substance

Ipamorelin

Primary target
GHS-R1a
Distinction
short GH pulse; human PK available
Status note
unapproved; WADA-prohibited

Substance

GHRP-2 / GHRP-6

Primary target
GHS-R1a
Distinction
older secretagogues; stronger ACTH/cortisol or appetite signals in preclinical comparisons
Status note
unapproved; WADA-prohibited

Substance

CJC-1295 / Mod GRF 1-29

Primary target
GHRH receptor
Distinction
different pathway; communities combine both axes
Status note
not FDA-approved; WADA-covered

Substance

Sermorelin

Primary target
GHRH receptor
Distinction
GHRH analogue with its own regulatory history
Status note
check current local product status

Substance

Tesamorelin

Primary target
GHRH receptor
Distinction
approved for one defined US indication; not interchangeable
Status note
FDA approval only for specified HIV lipodystrophy indication

Combinations / stacks

The reference mainly mentions combinations with GHRH analogues. No validated safety or efficacy protocol exists for these community stacks; effects and adverse effects may add up.

  • CJC-1295 without DAC (Mod GRF 1-29) plus Ipamorelin is described as a dual-receptor strategy.
  • CJC-1295 with DAC has a different duration and must not be treated as identical.
  • Tesamorelin and Sermorelin act at the GHRH receptor; approved Tesamorelin data do not validate combination with Ipamorelin.
  • BPC-157 is sometimes added in recovery communities, without robust clinical evidence for the combination.

Frequently asked questions

Is Ipamorelin an approved medicine?

No. It has no FDA-approved human use or approved dose for the goals discussed here.

Is 2 mg, 5 mg or 10 mg a dose?

No. It is the claimed total vial amount. A single volume also depends on added fluid.

How are U-100 units calculated?

U-100 means 100 units per ml. Calculate concentration from vial amount and fluid, then target amount ÷ concentration × 100.

What community ranges are commonly cited?

The reference describes 100–300 µg per administration, one to three times daily and 8–12-week cycles. These are unvalidated and not recommendations.

Are male and female schedules different?

Published research has not established sex-specific subcutaneous standard dosing for these community goals.

How long does reconstituted material last?

The reference says about 28 days refrigerated. Without product-specific stability data this is not a reliable guarantee.

What tests are discussed?

Mainly IGF-1, fasting glucose/HbA1c, lipids, thyroid markers, fluid retention and sleep-apnoea symptoms. No validated community monitoring standard exists.

Is Ipamorelin permitted in sport?

No. The 2026 WADA List expressly names Ipamorelin and prohibits it at all times.

Does a COA prove safe use?

No. Depending on scope it may describe identity or purity, but does not automatically prove content, sterility, endotoxins, stability or clinical suitability.

Why show the numbers at all?

To make widely circulated claims transparent and place their limitations next to them. Visibility is not endorsement.

Sources

Regulatory primary sources and studies support the assessment. The reference page is used only for community schedules; advertising, shops, discount codes and affiliate links were excluded.

Community reference

Peptide Dosing Protocols — Ipamorelin guide

Source used for the community schedules, calculations, handling claims and FAQ topics; commercial content excluded.

Official source

FDA — Certain bulk drug substances that may present significant safety risks

Current 503B Category 2 entry and FDA safety concerns for Ipamorelin acetate.

Official source

FDA PCAC — Ipamorelin-related bulk drug substances review

2024 evidence and safety review, including route-specific gaps and the 503A recommendation.

Official source

WADA — 2026 Prohibited List

Ipamorelin is listed in S2.2.4 among GH secretagogues and ghrelin mimetics prohibited at all times.

Research publication

Raun et al. (1998) — Ipamorelin, the first selective GH secretagogue

Preclinical pharmacological characterisation in rat and swine models.

Research publication

Gobburu et al. (1999) — Human PK/PD modelling

Phase-I intravenous pharmacokinetics and growth-hormone response in healthy male volunteers.

Research publication

Beck et al. (2014) — Phase-II postoperative ileus trial

Randomised IV study in bowel-resection patients; no significant efficacy difference.

Trial registry

ClinicalTrials.gov — NCT00672074

Official registry record for the completed 117-participant phase-II study.